Status:
COMPLETED
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The primary purpose of the study is to determine the time to progression of the combination of study drug (AG-013736) and docetaxel versus docetaxel alone in patients who have not received prior chemo...
Eligibility Criteria
Inclusion
- Female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease)
- Adequate bone marrow, liver, and renal function
Exclusion
- Adjuvant chemotherapy given in the past 12 months
- Uncontrolled brain metastases
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
174 Patients enrolled
Trial Details
Trial ID
NCT00076024
Start Date
February 1 2004
End Date
November 1 2008
Last Update
June 26 2012
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Tucson, Arizona, United States, 85724-5024
2
Pfizer Investigational Site
Tucson, Arizona, United States, 85724
3
Pfizer Investigational Site
Berkeley, California, United States, 94704
4
Pfizer Investigational Site
Montebello, California, United States, 90640